Zhongao Biomedical

Zhongao Biomedical Technology (Guangzhou) Co., Ltd. is a Chinese biotechnology company specializing in the research, development, and commercialization of recombinant protein therapeutics for regenerative medicine. The company is a pioneer in the clinical application of fibroblast growth factors (FGFs), particularly recombinant human acidic fibroblast growth factor (rh-aFGF). Its lead products are approved in China for the treatment of deep second-degree burns, chronic skin ulcers, and surgical wound healing. Zhongao Biomedical utilizes a proprietary high-efficiency protein expression and purification platform to produce biologics with high bioactivity and stability. The company was co-founded by leading scientists in the growth factor field, including Academician Li Xiaokun, and maintains strong ties with academic research centers. Beyond wound care, the company is expanding its pipeline into ophthalmology and dermatology to address unmet needs in tissue repair. Headquartered in Guangzhou, it operates GMP-certified manufacturing facilities to support its growing commercial portfolio.